Trial Profile
Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 15 Mar 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 15 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00870285).